Stay updated on Nivolumab Plus Ipilimumab in Metastatic Cancer Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Plus Ipilimumab in Metastatic Cancer Clinical Trial page.

Latest updates to the Nivolumab Plus Ipilimumab in Metastatic Cancer Clinical Trial page
- Check6 days agoChange DetectedThe page now displays Revision: v3.3.2. The previous Revision: v3.3.1 entry has been removed.SummaryDifference0.0%

- Check13 days agoChange DetectedRevision: v3.3.1 was added and v3.2.0 was removed on the page, reflecting a minor update to the document metadata. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check21 days agoChange DetectedRemoved the government funding/operating status notice from the page. The study details and other content remain unchanged.SummaryDifference0.3%

- Check35 days agoChange DetectedResults have been posted and key outcomes are now presented on the page. The updates include the results posting dates and outcome measures such as CBR, ORR, PFS, and OS.SummaryDifference0.4%

- Check64 days agoChange DetectedUpgrade to v3.2.0 with a government operating-status notice and links to status pages; removes the previous v3.1.0 reference.SummaryDifference1%

- Check71 days agoChange DetectedVersion updated from v3.0.2 to v3.1.0.SummaryDifference0.0%

Stay in the know with updates to Nivolumab Plus Ipilimumab in Metastatic Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Plus Ipilimumab in Metastatic Cancer Clinical Trial page.